The slumping economy is accelerating a trend in biotech toward the virtual-company model in which drug development is outsourced. There's worry it could go too far.
A broad swath of the San Diego tech industry says changes in how patents are awarded and limits on lawsuit damages would unfairly harm the 'little guy.'